Phase 4 N=233 Randomized Single-blind Supportive Care

Lidocaine Jelly for Pain Control During Mohs Surgery

Pain · Satisfaction, Consumer

Bottom Line

View on ClinicalTrials.gov: NCT03595449 ↗

Enrolled (actual)

233

Serious AEs

0.0%

Results posted

Jun 2021

Primary outcome: Primary: Mean Change in Patient Perception of Pain Score — 0.5; 0.3 score on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Lidocaine jelly (Drug); Surgilube (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Mayo Clinic
Primary completion: Aug 2020

Outcome Measures

Outcome	Result	p-value
PRIMARY Mean Change in Patient Perception of Pain Score	0.5; 0.3	—
SECONDARY Mean Total Amount of Intervention (Lidocaine or Surgilube) Used	28.1; 24.4	—

Summary

Does the use of lidocaine jelly during Mohs surgery on the nose decrease the total amount of lidocaine used during surgery. Does patient satisfaction improve when lidocaine jelly is used during Mohs surgery of the nose?

Eligibility Criteria

Inclusion criteria

Patients having Mohs surgery on the nose who are able to consent to the study >18 years old

Exclusion criteria

unable to consent for themselves known allergy to lidocaine Mohs surgery in locations other than the nose

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03595449). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.